Please login to the form below

Not currently logged in
Email:
Password:

myelofibrosis

This page shows the latest myelofibrosis news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Brexit reshuffle brings new health minister, Celgene thalassemia success, Wellcome read to leap into future

Daily Brief: Brexit reshuffle brings new health minister, Celgene thalassemia success, Wellcome read to leap into future

The companies are also developing luspatercept for the treatment of myelofibrosis.

Latest news

More from news
Approximately 8 fully matching, plus 43 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Celgene will pay approximately $1.1bn upfront for Impact and further contingent payments based on regulatory approval for fedratinib in myelofibrosis and other indications could amount to $1.4bn. ... Acquisition company - remaining 90%. 9, 000. Impact

  • Pharma deals in August 2015 Pharma deals in August 2015

    Acquisition ‐ company. 1300. Promedior. BMS. PRM 151 recombinant pentraxin‐ 2 protein for idiopathic pulmonary fibrosis and myelofibrosis.

  • Pharma deals during November 2014 Pharma deals during November 2014

    Good news at last. Days after finally getting the FDA's go-ahead to resume development of its lead candidate, imetelsta, for myelofibrosis and myelodysplastic syndrome, Geron has signed a deal

  • NICE and ‘ultra orphans’ NICE and ‘ultra orphans’

    It won't, for example, affect medicines such as Novartis' treatment for myelofibrosis, a rare blood cancer of which there are only around 0.4 cases of the condition per 100,

  • Pharma deals during November 2013 Pharma deals during November 2013

    Pacritinib, an oral therapy, is currently in phase III development for patients with myelofibrosis and has activity against genetic mutations linked to myelofibrosis, leukaemia and certain solid tumours.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • THE OTHER SIDE OF...BLOOD CANCER

    He just never makes any time for me.”. Meet Sophie. What she suffers from you have probably never heard of: a blood cancer, or neoplasm, called  myelofibrosis.

  • THE OTHER SIDE OF...BLOOD CANCER

    He just never makes any time for me.”. Meet Sophie. What she suffers from you have probably never heard of: a blood cancer, or neoplasm, called  myelofibrosis.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics